Xtl Biopharmaceuticals (XTLB) Revenue Growth (1y) (2012 - 2018)
Xtl Biopharmaceuticals (XTLB) Revenue Growth (1y) (2012 - 2018) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | - |
| 2 | Nanobiotix | 1,905.61 Bn | 1,905.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,011.81 Bn | 1,011.81 Bn | - | - |
| 4 | BeOne Medicines | 467.29 Bn | 462.50 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 122.89 Bn | 115.65 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.64 Bn | 34.63 Bn | 959.66 Mn | 96.43% |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 164.94% |
| Jun 30, 2018 | -97.55% |
| Mar 31, 2018 | -10.44% |
| Sep 30, 2014 | -39.32% |
| Jun 30, 2014 | -25.78% |
| Mar 31, 2014 | -12.78% |
| Dec 31, 2013 | 19.50% |
| Sep 30, 2013 | 37.90% |
| Jun 30, 2013 | -8.41% |
| Mar 31, 2013 | 4.34% |
| Dec 31, 2012 | -18.94% |
| Sep 30, 2012 | -35.16% |
| Jun 30, 2012 | -30.47% |